Abstracts Archive - Page 872 of 2425 - ACR Meeting Abstracts

Abstract Number: 1704 • 2019 ACR/ARP Annual Meeting
Efficacy of Leflunomide for Treatment of Vasculitis
NOURA MUSTAPHA ¹, Lillian Barra ², Simon Carette ³, David Cuthbertson ⁴, Nader A. Khalidi ⁵, Curry L. Koening ⁶, Carol Langford ⁷, Carol McAlear ⁸, Nataliya Milman ⁹, Larry Moreland ¹⁰, Paul Monach ¹¹, Philip Seo ¹², Ulrich Specks ¹³, Antoine Sreih ¹⁴, Steven Ytterberg ¹³, Peter Merkel ¹⁴, Christian Pagnoux¹⁵, CanVasc Canadian Vasculitis Research Network ¹⁶ and VCRC Vasculitis Clinical Research Consortium ⁸, ¹Hopital Notre Dame, Montreal, QC, Canada, ²St Joseph's health care, London, Canada, ³Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Canada, ⁴University of South Florida, Tampa, FL, ⁵McMaster University, Hamilton, ON, Canada, ⁶University of Utah Hospital, Salt Lake City, UT, ⁷Cleveland Clinic, Cleveland, OH, ⁸University of Pennsylvania, Division of Rheumatology, Philadelphia, ⁹Arthritis Centre at the Ottawa Hospital, Riverside Campus, Ottawa, Canada, ¹⁰University of Pittsburgh, PITTSBURGH, PA, ¹¹Brigham and Women's Hospital, Boston, MA, ¹²Johns Hopkins Medicine, Baltimore, MD, ¹³Mayo Clinic College of Medicine, Rochester, MN, ¹⁴University of Pennsylvania, Philadelphia, PA, ¹⁵Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ¹⁶Mount Sinai Hospital, Vasculitis clinic, toronto, ON, Canada
Background/Purpose: Only a few small case series, case reports, and one small clinical trial suggested some benefit of leflunomide (LEF) in ANCA-associated vasculitis and other…
Abstract Number: 1705 • 2019 ACR/ARP Annual Meeting
Cyclophosphamide Therapy for the Neurologic Involvement of Behçet’s Disease – Is It Superior to Azathioprine in Preventing Relapses?
Priscila Dias Cardoso Ribeiro ¹, Eduarda Bonelli Zarur ¹, Flávia Maria Matos Melo Campos Peixoto ¹, Pedro Matos ¹, Pedro Paulo de Alcantara Pedro ¹, Rywka Tenenbaum Medeiros Golebiovsk ¹, Livia Dutra ² and Alexandre Wagner de Souza³, ¹UNIFESP-EPM, Sao Paulo, Sao Paulo, Brazil, ²Escola Paulista de Medicina (EPM), Brazil, São Paulo, Brazil, ³UNIFESP-EPM, São Paulo, Sao Paulo, Brazil
Background/Purpose: Neurologic involvement is one of the most serious cause of long-term morbidity and mortality in Behçet’s disease (BD). To date, no controlled trials have…
Abstract Number: 1706 • 2019 ACR/ARP Annual Meeting
HLA-B*51 and Its Subtypes in Brazilian Patients with Behçet’s Disease
Joice Belem ¹, Ana Maria Fraga ², Luís Eduardo Coelho Andrade ¹ and Alexandre Wagner de Souza¹, ¹UNIFESP-EPM, São Paulo, Sao Paulo, Brazil, ²Fleury Group, São Paulo, Sao Paulo, Brazil
Background/Purpose: HLA-B*51 is considered the genetic marker mostly associated with Behçet's disease (BD), mainly in countries of the silk route, where its prevalence ranges from…
Abstract Number: 1707 • 2019 ACR/ARP Annual Meeting
IL-6 Promotes IgG4-related Disease by Inducing Fibroblast-dependent Tfh Cell and B Cell Differentiation Factors
Zongfei Ji¹, Rongyi Chen ², Xiaomeng Cui ², Lili Ma ², Xiufang Kong ³, Lingying Ma ², Ying Sun ², Xiaomin Dai ², Zhuojun Zhang ², Huiyong Chen ² and Lindi Jiang ², ¹Department of Rheumatology, Zhongshan hospital, Fudan University, Shanghai, China (People's Republic), ²Zhongshan hospital, Fudan University, Shanghai, China (People's Republic), ³University of Michigan & Fudan University, Ann Arbor, MI
Background/Purpose: Considering the unsatisfied effect of conventional therapy, to investigate the pathogenesis of IgG4-related disease (IgG4-RD) is crucial to explore novel treatment strategies. This study…
Abstract Number: 1708 • 2019 ACR/ARP Annual Meeting
Azathioprine and Glucocorticoid Combination Might Be a Good Treatment Option to Achieve Remission in Patients with IgG4-related Disease
Aydan Köken Avşar¹, Onay Gercik ², Gercek Can ³, Berrin Zengin ⁴, Sinem Burcu Kocaer ⁵, Atilla Okan Kılıç ⁶, Sadettin Uslu ⁷, Ali Karakaş ⁵, Merih Birlik ⁵, Servet Akar ⁸ and Fatos Onen ⁹, ¹Dokuz Eylul University School of Medicine, Rheumatology,, Türkiye, Izmir, Turkey, ²Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ³Dokuz Eylul University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Izmir, Turkey, ⁴Dokuz Eylul University School of Medicine, Rheumatology,, Turkey,Izmir, Izmir, Turkey, ⁵Division of Rheumatology, Dokuz Eylül University School of Medicine, İzmir, Turkey, Turkey,Izmir, Izmir, Turkey, ⁶Dokuz Eylul University School of Medicine, Internal Medıcıne, Turkey,Izmir, Izmir, Turkey, ⁷Division of Rheumatology, Dokuz Eylül University School of Medicine, İzmir, Turkey, Izmir, Turkey, ⁸Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, ⁹Dokuz Eylul University School of Medicine, Division of Rheumatology, İzmir, Turkey
Background/Purpose: IgG4-related disease is a recently recognised inflammatory disease of unkown etiology, often seen in men over the age of 50 and may affect many…
Abstract Number: 1709 • 2019 ACR/ARP Annual Meeting
Juvenile-Onset IgG4-Related Disease: A Systematic Review
Eduardo Martin-Nares¹, Talia Díaz-Prieto ², Enrique Faugier-Fuentes ², Luis A. Aparicio Vera ² and Gabriela Hernandez-Molina ¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Rheumatology, Hospital Infantil de México Federico Gómez, Mexico City, Mexico
Background/Purpose: IgG4-related disease (IgG4-RD) presenting in the pediatric age is rare. Natural history and outcomes are not well defined. The aim of this study was…
Abstract Number: 1710 • 2019 ACR/ARP Annual Meeting
Chemokine and Cytokine Tear Profile of Patients with IgG4-Related Disease
Eduardo Martin-Nares¹, Luis Llorente ¹, Guadalupe Lima ¹, Diego Hernández-Ramírez ¹, Isela Chan-Campos ¹, Vanessa Saavedra-González ¹ and Gabriela Hernandez-Molina ¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: The lacrimal gland is frequently involved in both IgG4-related disease (IgG4-RD) and Sjögren’s syndrome (SS) and presents with swelling and/or dry eye symptoms. Although…
Abstract Number: 1711 • 2019 ACR/ARP Annual Meeting
Distinctive Imaging Features Between IgG4-Related Ophthalmic Disease and Graves’ Orbitopathy: A Comparative Study
Eduardo Martin-Nares¹, Oziel Amaya-Piña ², Rosa Delia Delgado Hernández ² and Gabriela Hernandez-Molina ¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Radiology and Molecular Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: IgG4-related ophthalmic disease (IgG4-ROD) may present as a cause of orbital myositis leading to proptosis and diplopia. This clinical scenario can be mistakenly diagnosed…
Abstract Number: 1712 • 2019 ACR/ARP Annual Meeting
Head and Neck Involvement of IgA Vasculitis: A Case-Control Study
Michel Villatoro-Villar¹, David Wetter ¹, Cynthia Crowson ², Kenneth Warrington ¹ and Matthew Koster ¹, ¹Mayo Clinic Rochester, Rochester, MN, ²Mayo Clinic Rochester, Rochester
Background/Purpose: IgA vasculitis (IgAV) is an immune-complex mediated, small-vessel vasculitis which predominantly involves the skin on the lower extremities. Head and neck involvement is rarely…
Abstract Number: 1713 • 2019 ACR/ARP Annual Meeting
Drug-induced IgA Vasculitis: Data from the French Pharmacovigilance Network and the WHO VigiBase
CAMILLE RASMUSSEN¹, MYLENE TISSEYRE ², JULIE GARON-CZMIL ², MARINA ATZENHOFFER ³, Loïc Guillevin ⁴, LAURENT CHOUCHANA ² and Benjamin Terrier ⁴, ¹Cochin Hospital, National Referral Center for Rare Systemic Autoimmune Diseases, PARIS, PARIS, France, ²PHARMACOVIGILANCE, COCHIN HOSPITAL, PARIS, PARIS, France, ³PHARMACOVIGILANCE CENTER LYON, FRANCE, LYON, France, ⁴National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France
Background/Purpose: IgA vasculitis (IgAV) is an immune complex small-vessel vasculitis, with IgA1-dominant immune deposits. Drug-induced IgAV were rarely reported in the literature, but no systematic…
Abstract Number: 1714 • 2019 ACR/ARP Annual Meeting
Can We Predict Early Relapses in Adult IgA Vasculitis?
Jaka Ostrovrsnik¹, Ziga Rotar ¹, Matija Tomsic ¹ and Alojzija Hocevar ¹, ¹Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia
Background/Purpose: In adults, IgA vasculitis (IgAV) frequently takes a severe course in the acute phase of the disease. Data on long term outcomes is limited.…
Abstract Number: 1715 • 2019 ACR/ARP Annual Meeting
Predictors of Gastrointestinal and Renal Involvement in Adult IgA Vasculitis
Alojzija Hocevar¹, Ziga Rotar ² and Matija Tomšič ³, ¹Department of Rheumatology, University Medical Center Ljubljana, Slovenia, LJUBLJANA, Slovenia, ²UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ³Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, LJUBLJANA, Slovenia
Background/Purpose: IgA vasculitis (IgAV) is a common vasculitis of adult population, yet the disease in adults is still poorly defined. The aim of our study…
Abstract Number: 1716 • 2019 ACR/ARP Annual Meeting
Poor-Prognosis Factors of Systemic Vasculitides with Gastrointestinal Involvement: Data from a Large Retrospective Study
Segolene Gendreau¹, Benjamin Thoreau ², François Maurier ³, Tiphaine Goulenok ¹, Laure Frumholtz ¹, Arsène Mékinian ⁴, Saskia Oro ⁵, Charlotte Bernigaud ⁵, Alexandra Audemard ¹, Maxime Samson ⁶, Antoine Gaillet ¹, Romain Sonneville ¹, Jean-Benoit Arlet ¹, Adrien Mirouse ¹, Jean-Emmanuel Kahn ⁷, Aurélie Hummel ¹, Thomas Pires ⁸, Wendy Jourde ⁸, Eric Hachulla ⁹, Pierre-Louis Carron ¹⁰, Cécile-Audrey Durel ¹¹, Francoise Sarrot-Reynauld ¹², Nathalie Tieulie ¹³, Elisabeth Diot ¹⁴, Christian Agard ¹⁵, Guillaume Armengol ¹⁶, Alice Berezne ¹⁷, Christophe Deligny ¹⁸, Fleur Cohen ¹, Stanislas Faguer ¹⁹, Guillaume Le Guenno ²⁰, Mohamed Hamidou ¹⁵, Loïc Guillevin ²¹ and Benjamin Terrier ²¹, ¹APHP, Paris, France, ²CHU Tours, Tours, France, ³Service de Médecine Interne, Hôpital Belle Isle, Metz, Metz, France, ⁴Hôpital Saint-Antoine, APHP, Paris, Paris, France, ⁵APHP, Creteil, France, ⁶Service de Médecine Interne et Immunologie Clinique, CHU Dijon Bourgogne, Hôpital François Mitterrand, Dijon ; Université Bourgogne-Franche Comté, INSERM, EFS BFC, UMR1098, F-21000 Dijon, Dijon, France, ⁷APHP, Boulogne Billancourt, France, ⁸CHU Bordeaux, Bordeaux, France, ⁹CHU Lille, Lille, France, ¹⁰Grenoble, Grenoble, France, ¹¹Department of Internal Medicine, Hôpital Edouard Herriot, Lyon, France, Lyon, France, ¹²CHU Grenoble, Grenoble, France, ¹³University Hospital of Nice, Nice, France, ¹⁴APHP, Tours, France, ¹⁵CHU Nantes, Nantes, France, ¹⁶CHU Rouen, Rouen, France, ¹⁷CH Annecy Genevois, Annecy, France, ¹⁸CHU Martinique, Fort de France, France, ¹⁹CHU Toulouse, Toulouse, France, ²⁰CHU Clermont Ferrand, Clermont Ferrand, France, ²¹National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France
Background/Purpose: Gastrointestinal (GI) involvement was described as a poor-prognosis factor of systemic necrotizing vasculitides. However, the prognostic impact of GI involvement may vary according to…
Abstract Number: 1717 • 2019 ACR/ARP Annual Meeting
Identifying Patterns of Histopathologic Presentation in CNS Vasculitis
Chan Mi Lee¹, Richard Prayson ², Marcia Leon Rabanal ³, Leonard Calabrese ³ and Rula Hajj-ali ³, ¹Cleveland Clinic Lerner College of Medicine of Case Western Reserve University/Cleveland Clinic, Cleveland, OH, ²Anatomic Pathology/Cleveland Clinic, Cleveland, OH, ³Rheumatologic and Immunologic Disease/Cleveland Clinic, Cleveland, OH
Background/Purpose: Primary central nervous system vasculitis (CNS-V) is vasculitis confined to the brain, spinal cord and meninges. It is a rare condition with unknown pathogenesis.…
Abstract Number: 1718 • 2019 ACR/ARP Annual Meeting
Geographic Disparities in Mortality Rates of Vasculitis in the United States: 1999 to 2017
Alicia Rodriguez-Pla¹, ¹University of Arizona/Banner Health Medical Center, Tucson, AZ
Background/Purpose: Earlier diagnosis and less toxic immunosuppressive therapies have improved the survival of patients with vasculitis. Current data on mortality rates of vasculitis are limited.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].